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of Th1 responses. Chen et al. showed that upon chal-
lenge with protein antigen, TCCR-deficient (TCCR/)
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production, as well as reduced IgG2a production com-Faculty of Medicine
pared to wild-type mice (Chen et al., 2000). Moreover,Imperial College
there was a profound defect in clearance of ListeriaLondon SW7 2AK
monocytogenes in these TCCR-deficient mice. An IL-2 Laboratory of Immunoregulation
12-driven Th1 response from enriched CD4 T cells fromNational Institute for Medical Research
TCCR/ mice stimulated in vitro was also significantlyThe Ridgeway
impaired as compared to wild-type mice. However, IL-Mill Hill
12-induced splenocyte proliferation and upregulation ofLondon NW7 1AA
the IL-12R1 and 2 expression upon Con A activationUnited Kingdom
of splenocytes was unimpaired. More recently, Yoshida
et al. showed that CD4 T cells obtained from WSX-
1/ mice (an alternative name for TCCR) showed re-
duced IFN production upon primary stimulation underTight control of Th1 immunity is essential to prevent
similar Th1-inducing conditions to those used by Chenimmunopathology. Central to control of the IFN-gene
et al. (2000) (IL-12, anti-IL-4, IL-2, Con A, and irradiatedis the transcription factor T-bet, whose induction is
spleen cells) (Yoshida et al., 2001). However, in contrastStat-1 dependent. IL-12 is dominant in directing Th1
to the findings of Chen et al., these T cells appeared todevelopment, while synergizing with IL-18 for IFN
recover with respect to IFNproduction upon secondaryproduction from differentiated Th1 cells. In this issue
restimulation in vitro. WSX-1/ mice were markedlyof Immunity, IL-27 is described, which acts in synergy
more susceptible to Leishmania major infection, show-with IL-12 early in Th1 development from naive T cells
ing increased footpad swelling and increased numbersvia the receptor TCCR/WSX-1. We review the coordi-
of organisms recovered from tissues as compared tonation of these checkpoints in Th1 development and
wild-type C57Bl/6 mice. There was impaired IFN pro-function.
duction early in the infection (at 2 weeks), although, in
accordance with the in vitro data on Th1 development,Appropriate induction of a Th1 response is required for
at 4 weeks after infection, L. major-induced IFN pro-effective eradication of intracellular pathogens and in-
duction by draining lymph node cells restimulated involves macrophage activation and production of com-
vitro was equivalent in WSX-1/ and wild-type mice.plement fixing and opsonizing antibodies (Abbas et al.,
However, this recovery of IFN production was not obvi-1996; O’Garra, 1998; Murphy et al., 2000). This activity
ously associated with healing of the disease, since foot-requires optimal IFN production from Th1 cells. Initial
pad swelling and numbers of infiltrating organisms re-studies showed that IFN itself was required but not
mained elevated as compared to wild-type littermates.sufficient for the development of a Th1 response (Abbas
This early requirement for effective Th1 immunity in L.et al., 1996; O’Garra, 1998; Murphy et al., 2000). IL-12,
major clearance was paralleled by increased granulomaproduced by monocytes/macrophages and dendritic
formation to BCG. However, in this case hepatic myco-cells, was shown to be the dominant factor in develop-
bacterial counts were not affected, suggesting that otherment of the Th1 phenotype (Trinchieri, 1995; O’Garra,
mechanisms can control some bacterial infections.
1998; Murphy et al., 2000). Although required for effec-
Thus, both studies indicate that mice deficient in a func-
tive antimicrobial immunity, dysregulated Th1 re-
tional TCCR/WSX-1 receptor show impaired Th1 re-
sponses may lead to immunopathology and have been sponses accompanied by an impairment in the clear-
implicated in organ-specific autoimmunity (Powrie and ance of pathogens, including L. monocytogenes and
Coffman, 1993; O’Garra, 1998). Perhaps for this reason, L. major. However, the latter study suggests that this
Th1 development is tightly regulated and multiple requirement for signaling through TCCR/WSX-1 may be
checkpoints in addition to IFN and IL-12 have been most important early in an immune response.
identified. IL-27, described by Pflanz et al. in this issue of Immu-
In this issue of Immunity, Pflanz et al. describe a new nity, is identified as the ligand for TCCR/WSX-1 (Chen
heterodimeric cytokine, related to IL-12 and termed IL- et al., 2000; Yoshida et al., 2001). The authors show that
27, which acts early together with IL-12 to trigger IFN this cytokine is a heterodimer consisting of EBI3, an IL-
production by naive CD4 T cells. They also identify IL- 12 p40-related protein (Devergne et al., 1997), and p28,
27 as the ligand for TCCR/WSX-1 (Chen et al., 2000; a newly discovered IL-12 p35-related polypeptide
Yoshida et al., 2001), a novel member of the class I (Pflanz et al., 2002). Furthermore, expression of both
cytokine receptor family recently shown to be important components of the heterodimer is upregulated in anti-
for Th1 development. gen-presenting cells upon activation with LPS. IL-27
Two groups have shown that mice made deficient in induced significant proliferation of naive but not memory
the TCCR/WSX-1 receptor have significant impairment T cells (both in mouse and human systems) in the ab-
sence of IL-2. These findings are in keeping with a higher
level of mRNA expression for TCCR by undifferentiated3 Correspondence: aogarra@nimr.mrc.ac.uk
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Figure 1. Checkpoints in Th1 Development
Presentation of pathogen antigens to naive T cells by antigen-presenting cells (APC) induces IL-12R2 expression on T cells. APC-derived
IL-12, together with IL-27, initiates Th1 development. IL-27 signals through the T cell cytokine receptor (TCCR, also termed WSX-1). IL-12
acts via Stat4 to upregulate IFN production. Th1 development requires IFN itself, which activates Stat1 and induces expression of the
transcription factor T-bet. T-bet is a major Th1 commitment factor and transactivates the IFN- gene, as well as inducing chromatin remodeling
of the IFN- locus. IL-12 induces IL-18 receptor expression, which allows IL-18 to synergize with IL-12 to increase IFN production from
committed Th1 effectors. IL-18 signals via IL-1 receptor-associated kinase (IRAK) to activate NFB, and the combination of IL-12 and IL-18
activates GADD45 and p38 mitogen kinase signaling, all of which are major amplifiers of the IFN response. Memory CD4 T cells respond
to IL-23, an IL-12-related cytokine, which increases proliferation and may increase IFN production further.
CD4 T cells as compared to Th1 or Th2-polarized cells and thus IL-12-induced Stat4 activation was postulated
to be a commitment step to explain why Th2 cells cannot(Chen et al., 2000). It had previously been shown that
IL-12R2 was not expressed by naive CD4 T cells but produce IFN (Szabo et al., 1997; Rogge et al., 1997).
However, recently it was shown that ectopic expressionwas induced upon activation through the TCR, and its
expression was increased during IL-12-induced Th1 de- of the IL-12R2 in developing Th2 cells restored IL-12-
induced Stat4 activation and proliferation but not IFNvelopment (Szabo et al., 1997; Rogge et al., 1997). Since
IL-27 synergized with IL-12 for induction of IFNproduc- production (Heath et al., 2000; Nishikomori et al., 2000).
This suggests additional pathways for IFN induction.tion by naive T cells, this suggests that IL-27 may prime
T cells for subsequent IL-12-induction of IFN, or, con- The transcription factor T-bet has recently shown to
have an important role in Th1 development. T-bet wasversely, that both signals are required. However, Chen
et al. (2000) have shown that the TCCR/WSX-1 receptor isolated from yeast two-hybrid analysis of binding of
cDNAs from an activated Th1 library to a Th1-specific(for IL-27) was not required for the induction of the IL-
12R on splenocytes upon activation. Thus, IL-27 ap- portion of the IL-2 promoter, coupled with RDA (Szabo
et al., 2000). T-bet expression correlated with IFN pro-pears to act at an early stage in Th1 development in a
manner distinct from IL-12. duction by Th1 cells and NK cells, and T-bet was a
potent transactivator of the IFN gene. Retroviral geneThe biology of IL-27 distinguishes it from the earlier
described cofactor for IL-12-driven Th1 development, transduction of T-bet into primary T cells or developing
Th2 cells could activate IFN production (Szabo et al.,IL-18, which appears to act later in Th1 development
(Okamura et al., 1995; Robinson et al., 1997). IL-18 is 2000). T-bet-deficient mice had default Th2 develop-
ment and developed spontaneous airway changes simi-an IL-1 family member which, as well as enhancing IL-
12-driven Th1 development, shows pronounced synergy lar to those of asthma (a Th2-driven disease) (Finotto et
al., 2002), although it is of note that T-bet did not appearwith IL-12 for secretion of IFN by differentiated Th1
cells (Robinson et al., 1997). Interestingly, IL-18 with IL- to be required for IFN production by CD8 T cells
(Szabo et al., 2002). T-bet induction and Th1 develop-12 can induce IFN production from Th1 cells in the
absence of T cell receptor signaling (Robinson et al., ment could still occur in Stat4-deficient mice (Mullen et
al., 2001) when T cells were stimulated in the presence1997; Yang et al., 2001; Lertmemongkolchai et al., 2001),
thus augmenting antigen-specific Th1 immunity. The re- of anti-IL-4. Furthermore, ectopic expression of T-bet
by a retroviral vector induced IFN production fromceptor for IL-18 (an IL-1R family member) is induced by
IL-12 (Afkarian et al., 2002). Stat4/ T cells even when cultured in IL-4 and anti-IL-
12. T-bet thus appears to act before and independentlyIL-12 signals through Stat4 activation for the develop-
ment of Th1 responses (Szabo et al., 1997; Jacobson of IL-12-induced Stat4 activation in Th1 development
and induces chromatin remodeling of the IFN locus.et al., 1990; Kaplan et al., 1996), and loss of the IL-12R2
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S.Y., Murphy, T.L., and Murphy, K.M. (2002). Nat. Immunol. 3,However, other investigators reported that Stat4 activa-
549–557.tion could further increase T-bet expression (Grogan et
Chen, Q., Ghilardi, N., Wang, H., Baker, T., Xie, M.H., Gurney, A.,al., 2001). More recently, two groups have shown that
Grewal, I.S., and de Sauvage, F.J. (2000). Nature 407, 916–920.T-bet expression is induced in a Stat1-dependent man-
ner via IFN (Lighvani et al., 2001, Afkarian et al., 2002). Devergne, O., Birkenbach, M., and Kieff, E. (1997). Proc. Natl. Acad.
Sci. USA 94, 12041–12046.Indeed, Stat1-deficient T cells failed to express T-bet
despite IFN induction under Th1-polarizing conditions Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig,
S., Harris, J., Holland, S.M., Schreiber, R.D., and Casanova, J.L.(IL-12 and anti-IL-4) (Afkarian et al., 2002). These investi-
(2001). Science 293, 300–303.gators also showed that T-bet induced IL-12R2 expres-
sion and could do so independently of Stat1 but found Finotto, S., Neurath, M.F., Glickman, J.N., Qin, S., Lehr, H.A., Green,
F.H., Ackerman, K., Haley, K., Galle, P.R., Szabo, S.J., et al. (2002).no evidence for autoactivation of T-bet (Afkarian et al.,
Science 295, 336–338.2002). Thus, one reason for failure of T-bet-deficient T
cells to mount Th1 responses could be an inability to Grogan, J.L., Mohrs, M., Harmon, B., Lacy, D.A., Sedat, J.W., and
Locksley, R.M. (2001). Immunity 14, 205–215.induce the IL-12R2. However, expression of the IL-
12R2 was seen in Th1 cells derived from Stat1/ mice Heath, V.L., Showe, L., Crain, C., Barrat, F.J., Trinchieri, G., and
(Afkarian et al., 2002), which may indicate a T-bet-inde- O’Garra, A. (2000). J. Immunol. 164, 2861–2865.
pendent pathway to IL-12R2 expression that could also Jacobson, N.G., Szabo, S.J., Weber-Nordt, R.M., Zhong, Z.,
be via IL-27. It will be of interest to see if this is the Schreiber, R.D., Darnell, J.E., Jr., and Murphy, K.M. (1995). J. Exp.
case, and also whether IL-27 induces Stat1 activation Med. 181, 1755–1762.
or T-bet expression. The suggestion from the TCCR/ Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.F., New-
mice is, however, that IL-12R expression does not re- port, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., and Casa-
quire IL-27 signaling. Thus, any role of IL-27 in inducing nova, J.L. (1996). N. Engl. J. Med. 335, 1956–1961.
IL-12 responsiveness remains speculative (Chen et al., Kaplan, M.H., Sun, Y.L., Hoey, T., and Grusby, M.J. (1996). Nature
2000). 382, 174–177.
A number of other signaling pathways have been im-
Lertmemongkolchai, G., Cai, G., Hunter, C.A., and Bancroft, G.J.
plicated as potential checkpoints in Th1 development (2001). J. Immunol. 166, 1097–1105.
and IFN production, including IL-18 signaling via NFB
Lighvani, A.A., Frucht, D.M., Jankovic, D., Yamane, H., Aliberti, J.,(Robinson et al., 1997), p38 MAPK (Lu et al., 2001), and
Hissong, B.D., Nguyen, B.V., Gadina, M., Sher, A., Paul, W.E., and
GADD45 (Yang et al., 2001). Another IL-12-related cyto- O’Shea, J.J. (2001). Proc. Natl. Acad. Sci. USA 98, 15137–15142.
kine, IL-23, consisting of a novel protein, p19, which
Lu, B., Yu, H., Chow, C., Li, B., Zheng, W., Davis, R.J., and Flavell,binds to the p40 subunit of IL-12, has been reported to
R.A. (2001). Immunity 14, 583–590.
act selectively in proliferation and IFN production from
Mullen, A.C., High, F.A., Hutchins, A.S., Lee, H.W., Villarino, A.V.,memory T cells (Oppmann, et al., 2000).
Livingston, D.M., Kung, A.L., Cereb, N., Yao, T.P., Yang, S.Y., andThe definition of the IL-27 interaction with TCCR/
Reiner, S.L. (2001). Science 292, 1907–1910.
WSX-1 is a further step in understanding the complex
Murphy, K.M., Ouyang, W., Farrar, J.D., Yang, J., Ranganath, S.,checkpoints in Th1 development and underpins the im-
Asnagli, H., Afkarian, M., and Murphy, T.L. (2000). Annu. Rev. Immu-portance of multiple levels of control for IFN production
nol. 18, 451–494.for achieving optimal Th1 protective immunity to infec-
Neighbors, M., Xu, X., Barrat, F.J., Ruuls, S.R., Churakova, T., De-tion without induction of immunopathology. Perhaps
bets, R., Bazan, J.F., Kastelein, R.A., Abrams, J.S., and O’Garra, A.most important for protection from intracellular patho-
(2001). J. Exp. Med. 194, 343–354.gens are IL-12 and IL-18, which synergistically induce
Nishikomori, R., Ehrhardt, R.O., and Strober, W. (2000). J. Exp. Med.maximal IFN production from Th1 cells (Neighbors et
191, 847–858.al., 2001). These checkpoints in Th1 development are
O’Garra, A. (1998). Immunity 8, 275–283.summarized in Figure 1.
It is of note that dramatic clinical syndromes result Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tani-
from defects in the Th1 regulation pathway, including moto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995).
Nature 378, 88–91.IFNR, IL-12R, and Stat1 deficiency, which cause pro-
found immunodeficiency (Jouanguy et al., 1996; Otten- Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B.,
hoff et al., 1998; Dupuis et al., 2001). It will be of interest Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000). Immunity 13,
715–725.to see whether similar syndromes occur for T-bet, IL-
27, or TCCR/WSX-1 and whether specific targeting of Ottenhoff, T.H., Kumararatne, D., and Casanova, J.L. (1998). Immu-
these Th1 checkpoints will be useful for manipulating nol. Today 19, 491–494.
immunity to infection or ameliorating Th1-induced auto- Pflanz, S., Timans, J.C., Cheung, J., Roasles, R., Kanzler, H., Gilbert,
immune pathology. J., Hibbert, L., Churakova, T., Travis, M., Vaisberg, E., et al. (2002).
Immunity 16, this issue, 779–790.
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